Bayer said its eye treatment aflibercept showed positive results in a late-stage trial, including improved vision gains for ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy ...

Bayer AG won the backing of European Union regulators for its cardiology drug as the German company fights to offset the ...

Bayer's venerable testosterone replacement product ... Nubeqa is one of three drugs that the company is hoping will help it weather that impact on revenues, along with recently-approved diabetic ...

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastatic ...

Kyorin Pharmaceutical Co. Ltd. has acquired Bayer AG’s phase II obstructive sleep apnea candidate, BAY-2925976, in a deal worth €85M (US$89.3 million) plus sales-based royalties and commercial ...

Successful drug development is imperative to Bayer amid multiple challenges. The failure of a late-stage study on asundexian was a major setback for the company. BAYRY is also working to expand ...